Holen Sie sich die Stockscreener-App
29.66
0.20%
0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Is Alkermes plc (8AK) stock a momentum leaderJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - ulpravda.ru
Is Alkermes plc stock positioned for digital transformation2025 Growth vs Value & Capital Protection Trade Alerts - ulpravda.ru
Technical Reactions to ALKS Trends in Macro Strategies - Stock Traders Daily
Workboat Indexes - FinancialContent
Top Biotech Players REGN, INCY, PTCT Among Participants At J.P.Morgan Healthcare Conference 2026 - RTTNews
How FDA Breakthrough Therapy Status for Alixorexton Will Impact Alkermes (ALKS) Investors - Sahm
What dividend safety score for Alkermes plc stockMarket Sentiment Review & High Yield Equity Trading Tips - ulpravda.ru
Will Alkermes plc stock split attract more investorsJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - ulpravda.ru
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside - Seeking Alpha
Alkermes plcOrdinary Shares (NQ: ALKS - FinancialContent
Is Alkermes plc stock supported by innovation pipelineGold Moves & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Alkermes plc stock a good choice for value investors2025 Trading Volume Trends & Free Technical Confirmation Trade Alerts - ulpravda.ru
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug - Finviz
Alkermes plc's (NASDAQ:ALKS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data - Yahoo Finance
FDA Grants Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 - Sleep Review
Is Alkermes plc (8AK) stock a top pick for value investorsTrade Performance Summary & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Yahoo Finance UK
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - MSN
Alkermes to present at the 44th annual JP Morgan Healthcare Conference - MSN
Alkermes gains FDA breakthrough status for narcolepsy drug - MSN
FDA Grants Breakthrough Therapy Designation to Alixorexton for Narcolepsy Type 1 - HCPLive
Alkermes stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa
Alkermes stock rises after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Alkermes’ narcolepsy drug By Investing.com - Investing.com South Africa
Alkermes Gains FDA Breakthrough Status for Narcolepsy Drug - TipRanks
Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton - TradingView — Track All Markets
Form 8-KCurrent report - ADVFN
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 - Business Wire
Alkermes Plc (ALKS) Stock Analysis: Unveiling A 55% Upside Potential For Investors - DirectorsTalk Interviews
Deutsche Bank Initiates Coverage of Alkermes (ALKS) with Buy Recommendation - MSN
Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended June 30, 2013 - AOL.com
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock - MarketBeat
J.P. Morgan Healthcare Conference - marketscreener.com
Levels Update: Will Alkermes plc 8AK stock outperform global peersChart Signals & Short-Term Trading Alerts - moha.gov.vn
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.04 Million in Alkermes plc $ALKS - MarketBeat
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
User | punxsutawneyspirit.comAlkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Centessa narcolepsy data not superior to Alkermes, says Stifel - MSN
Trading the Move, Not the Narrative: (ALKS) Edition - Stock Traders Daily
Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS - MarketBeat
About the Alkermes Inspiration Grants® Program - CSRwire
Alkermes plc (ALKS) Stock Price History & Data - Traders Union
J.P. Morgan discloses trading in Avadel Pharmaceuticals amid takeover - Investing.com
Why Analysts are Rating Alkermes (ALKS) a Buy - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Alkermes plc stock benefit from commodity pricesTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
Why global investors buy Alkermes plc (8AK) stockEarnings Recap Report & Reliable Volume Spike Alerts - Bölüm Sonu Canavarı
ALKS (Alkermes) Other Current Payables : $0 Mil (As of Sep. 2025) - GuruFocus
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):